ResearchMoz

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

GBI Research
Published Date » 2012-07-10
No. Of Pages » 172

GBI Research, the leading business intelligence provider, has released its latest research, Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market. 

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. 

GBI Research also analyzed the promising pipeline molecules that are expected to be launched during the forecast period (2012-2018). The molecules are Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM. The launch of promising molecules is projected to add $2,979m in revenues by 2018. The novel molecules are expected to increase progression free survival, providing a better treatment option to cancer patients. The molecules are expected to address the safety and unmet needs. GBI Research analyzed 63 M&A deals, 95 licensing deals and 67 R&D collaboration agreements that took place during 20072011 and found that competitive activity is increasing in the oncology therapeutics market.

Scope

  • Data and analysis on the leading therapeutic classes in oncology. 
  • Market data on the promising molecules in the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer.
  • Key M&A activities and licensing agreements that took place from 20052011 in the oncology market.

Reasons to buy

  • Align your product portfolio to markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12

2 Novel Therapies in Oncology - Introduction 15

3 Novel Therapies in Oncology - Key Innovations and Technologies 16

3.1 Introduction 16
3.1.1 Increase in Cancer 17
3.1.2 Risk Factors for Cancer 17
3.2 Oncology Treatment Pathways 17
3.2.1 Chemotherapeutics 17
3.2.2 Targeted Therapies 18
3.3 Leading Marketed Drugs in Oncology 18
3.3.1 Rituxan/ MabThera 18
3.3.2 Herceptin 19
3.3.3 Gleevec/Glivec 20
3.3.4 Avastin 21
3.3.5 Eloxatin 21
3.3.6 Erbitux 22
3.3.7 Xeloda 22
3.3.8 Femara 23
3.3.9 Temodar 23
3.3.10 Tarceva 24
3.3.11 Taxotere 25
3.3.12 Revlimid 25
3.3.13 Alimta 26

4 Novel Therapies in Oncology - Leading Novel Drug Classes for the Future 27
4.1 Protein Kinase Inhibitors 27
4.2 Vaccines 28
4.2.1 Tumor Cell Vaccines 29
4.2.2 Antigen Vaccines 29
4.2.3 Dendritic Cell Vaccines 30
4.2.4 Anti-Idiotype vaccines 30

5 Novel Therapies in Oncology - Opportunity and Unmet Need Analysis 31
5.1 Breast Cancer 31
5.2 Colorectal Cancer 33
5.3 NHL 34
5.4 NSCLC 36
5.5 Prostate Cancer 38
5.6 Ovarian Cancer 39
5.7 Cervical Cancer 40
5.8 Head and Neck Cancer 41

6 Novel Therapies in Oncology - Product Pipeline Analysis 43
6.1 Introduction 43
6.2 Breast Cancer 47
6.2.1 Breast Cancer Pipeline - Introduction 47
6.2.2 Breast Cancer Pipeline - Analysis by Therapeutic Class 48
6.2.3 Breast Cancer Pipeline - Pre-Clinical 53
6.2.4 Breast Cancer Pipeline - Discovery 54
6.2.5 Breast Cancer Pipeline - Phase I 55
6.2.6 Breast Cancer Pipeline - Phase II 57
6.2.7 Breast Cancer Pipeline - Phase III 61
6.2.8 Breast Cancer Pipeline - NDA Filed 61
6.3 Colorectal Cancer 62
6.3.1 Colorectal Cancer Pipeline - Introduction 62
6.3.2 Colorectal Cancer Pipeline - Analysis by Therapeutic Class 63
6.3.3 Colorectal Cancer Pipeline - Pre-Clinical 68
6.3.4 Colorectal Cancer Pipeline - Discovery 68
6.3.5 Colorectal Cancer Pipeline - Phase I 69
6.3.6 Colorectal Cancer Pipeline - Phase II 71
6.3.7 Colorectal Cancer Pipeline - Phase III 74
6.4 NHL 75
6.4.1 NHL Pipeline - Introduction 75
6.4.2 NHL Pipeline - Analysis by Therapeutic Class 76
6.4.3 NHL Pipeline - Pre-Clinical 81
6.4.4 NHL Pipeline - Discovery 81
6.4.5 NHL Pipeline - Phase I 82
6.4.6 NHL Pipeline - Phase II 84
6.4.7 NHL Pipeline - Phase III 85
6.4.8 NHL Pipeline - NDA Filed 85
6.5 NSCLC 86
6.5.1 NSCLC Pipeline - Introduction 86
6.5.2 NSCLC Pipeline - Analysis by Therapeutic Class 87
6.5.3 NSCLC Pipeline - Pre-Clinical 93
6.5.4 NSCLC Pipeline - Discovery 94
6.5.5 NSCLC Pipeline - Phase I 94
6.5.6 NSCLC Pipeline - Phase II 95
6.5.7 NSCLC Pipeline - Phase III 97
6.5.8 NSCLC Pipeline - NDA Filed 98
6.6 Prostate Cancer 99
6.6.1 Prostate Cancer Pipeline - Introduction 99
6.6.2 Prostate Cancer Pipeline - Analysis by Therapeutic Class 100
6.6.3 Prostate Cancer Pipeline - Pre-Clinical 106
6.6.4 Prostate Cancer Pipeline - Discovery 107
6.6.5 Prostate Cancer Pipeline - Phase I 108
6.6.6 Prostate Cancer Pipeline - Phase II 109
6.6.7 Prostate Cancer Pipeline - Phase III 111
6.6.8 Prostate Cancer Pipeline - NDA Filed 112
6.7 Ovarian Cancer 112
6.7.1 Ovarian Cancer Pipeline - Introduction 112
6.7.2 Ovarian Cancer Pipeline - Analysis by Therapeutic Class 113
6.7.3 Ovarian Cancer Pipeline - Pre-Clinical 117
6.7.4 Ovarian Cancer Pipeline - Discovery 118
6.7.5 Ovarian Cancer Pipeline - Phase I 119
6.7.6 Ovarian Cancer Pipeline - Phase II 120
6.7.7 Ovarian Cancer Pipeline - Phase III 122
6.7.8 Ovarian Cancer Pipeline - NDA Filed 122
6.8 Cervical Cancer 123
6.8.1 Cervical Cancer Pipeline - Introduction 123
6.8.2 Cervical Cancer Pipeline - Analysis by Therapeutic Class 124
6.8.3 Cervical Cancer Pipeline - Pre-Clinical 128
6.8.4 Cervical Cancer Pipeline - Phase I 128
6.8.5 Cervical Cancer Pipeline - Phase II 129
6.8.6 Cervical Cancer Pipeline - Phase III 129
6.9 Head and Neck Cancer 130
6.9.1 Head and Neck Cancer Pipeline - Introduction 130
6.9.2 Head and Neck Cancer Pipeline - Analysis by Therapeutic Class 131
6.9.3 Head and Neck Cancer Pipeline - Pre-Clinical 135
6.9.4 Head and Neck Cancer Pipeline - Discovery 135
6.9.5 Head and Neck Cancer Pipeline - Phase I 136
6.9.6 Head and Neck Cancer Pipeline - Phase II 137
6.9.7 Head and Neck Cancer Pipeline - Phase III 139

7 Novel Therapies In Oncology - Promising Molecules 140
7.1 T-DM1 140
7.1.1 Introduction 140
7.1.2 Mechanism of Action 140
7.1.3 Revenues 140
7.2 Afinitor (everolimus) 141
7.2.1 Introduction 141
7.2.2 Mechanism of Action 141
7.2.3 Revenues 142
7.3 Iniparib (E75) 143
7.3.1 Introduction 143
7.3.2 Mechanism of Action 143
7.3.3 Revenues 144
7.4 Afatinib 145
7.4.1 Introduction 145
7.4.2 Mechanism of Action 145
7.4.3 Revenues 145
7.5 Avastin 146
7.5.1 Introduction 146
7.5.2 Mechanism of Action 146
7.5.3 Revenues 146
7.6 Farletuzumab 147
7.6.1 Introduction 147
7.6.2 Mechanism of Action 147
7.6.3 Revenues 148
7.7 V503 149
7.7.1 Introduction 149
7.7.2 Mechanism of Action 149
7.7.3 Revenues 149
7.8 Tykerb 150
7.8.1 Introduction 150
7.8.2 Mechanism of Action 150
7.8.3 Revenues 151
7.9 TheraCIM 152
7.9.1 Introduction 152
7.9.2 Mechanism of Action 152
7.9.3 Revenues 153

8 Novel Therapies In Oncology - Strategic Consolidations 154
8.1 M&A Landscape 154
8.1.1 M&A Deals by Year 156
8.1.2 M&A Deals by Geography 157
8.1.3 M&A Deals by Value 158
8.1.4 M&A Deals by Deal Type 159
8.2 R&D Licensing Agreements 160
8.2.1 Deals by Year 161
8.2.2 Deals by Geography 162
8.2.3 Deals by Value 163
8.3 Co-Development Agreements 164
8.3.1 Deals by Year 165
8.3.2 Deals by Geography 166
8.3.3 Deals by Value 167

9 Novel Therapies In Oncology - Appendix 168
9.1 Market Definitions 168
9.2 Abbreviations 168
9.3 Sources 169
9.4 Research Methodology 170
9.4.1 Coverage 170
9.4.2 Secondary Research 170
9.4.3 Primary Research 171
9.4.4 Section Wise Methodology 171
9.4.5 Expert Panel Validation 171
9.5 Contact Us 172
9.6 Disclaimer 172

List of Tables


Table 1: Novel Therapies in Oncology, Oncology Clinical Trials, 2011 16
Table 2: Novel Therapies in Oncology, Pipeline by Developmental Phase, 2011 43
Table 3: Novel Therapies in Oncology, Pipeline by Indication, 2011 45
Table 4: Novel Therapies in Oncology, Pipeline by Therapeutic Class, 2011 46
Table 5: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase, 2011 47
Table 6: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 48
Table 7: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 49
Table 8: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 50
Table 9: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 51
Table 10: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 52
Table 11: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 53
Table 12: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Stage Molecules, 2011 54
Table 13: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules, 2011 55
Table 14: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules, 2011 57
Table 15: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules, 2011 61
Table 16: Novel Therapies in Oncology, Breast Cancer Pipeline, NDA Filed Molecules, 2011 61
Table 17: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase, 2011 62
Table 18: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 63
Table 19: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 64
Table 20: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class , 2011 65
Table 21: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 66
Table 22: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 67
Table 23: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 68
Table 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Stage Molecules, 2011 68
Table 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules, 2011 69
Table 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules, 2011 71
Table 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules, 2011 74
Table 28: Novel Therapies in Oncology, NHL Pipeline by Phase, 2011 75
Table 29: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 76
Table 30: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class, 2011 77
Table 31: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class, 2011 78
Table 32: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class, 2011 79
Table 33: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class, 2011 80
Table 34: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Stage Molecules, 2011 81
Table 35: Novel Therapies in Oncology, NHL Pipeline, Discovery Stage Molecules, 2011 81
Table 36: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules, 2011 82
Table 37: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules, 2011 84
Table 38: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules, 2011 85
Table 39: Novel Therapies in Oncology, NHL Pipeline, NDA Filed Molecules, 2011 85
Table 40: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase, 2011 86
Table 41: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 87
Table 42: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class, 2011 88
Table 43: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class, 2011 89
Table 44: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class, 2011 90
Table 45: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class, 2011 91
Table 46: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 92
Table 47: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Stage Molecules, 2011 93
Table 48: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Stage Molecules, 2011 94
Table 49: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules, 2011 94
Table 50: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules, 2011 95
Table 51: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules, 2011 97
Table 52: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules, 2011 98
Table 53: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase, 2011 99
Table 54: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 101
Table 55: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 102
Table 56: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 103
Table 57: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 104
Table 58: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 105
Table 59: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 106
Table 60: Novel Therapies in Oncology, Prostate Cancer Pipeline, Discovery Stage Molecules, 2011 107
Table 61: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules, 2011 108
Table 62: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules, 2011 109
Table 63: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules, 2011 111
Table 64: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules, 2011 112
Table 65: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase, 2011 112
Table 66: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 113
Table 67: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class,2011 114
Table 68: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 115
Table 69: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 116
Table 70: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 117
Table 71: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Discovery Stage Molecules, 2011 118
Table 72: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules, 2011 119
Table 73: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules, 2011 120
Table 74: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 122
Table 75: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 122
Table 76: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase, 2011 123
Table 77: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 124
Table 78: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 125
Table 79: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 126
Table 80: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 127
Table 81: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 128
Table 82: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules, 2011 128
Table 83: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules, 2011 129
Table 84: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules, 2011 129
Table 85: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase, 2011 130
Table 86: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 131
Table 87: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 131
Table 88: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 132
Table 89: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 133
Table 90: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 134
Table 91: Novel Therapies in Oncology, Head And Neck Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 135
Table 92: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Stage Molecules, 2011 135
Table 93: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules, 2011 136
Table 94: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules, 2011 137
Table 95: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules, 2011 139
Table 96: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018 140
Table 97: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018 142
Table 98: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018 144
Table 99: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018 145
Table 100: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018 147
Table 101: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2015-2018 148
Table 102: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018 149
Table 103: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018 151
Table 104: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018 153
Table 105: Novel Therapies in Oncology, Global, Major M&A Deals, 2007-2011 154
Table 106: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011 156
Table 107: Novel Therapies in Oncology, Global, M&A Deals by Geography, 2007-2011 157
Table 108: Novel Therapies in Oncology, Global, M&A Deals by Value, 2007-2011 158
Table 109: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, 2007-2011 159
Table 110: Novel Therapies in Oncology, Global, Major R&D Licensing Deals, 2007-2011 160
Table 111: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011 161
Table 112: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, 2007-2011 162
Table 113: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, 2007-2011 163
Table 114: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 164
Table 115: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 165
Table 116: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, 2007-2011 166
Table 117: Novel Therapies in Oncology, Global, Co-Development Deals by Value, 2007-2011 167

List of Figures


Figure 1: Novel Therapies in Oncology, Oncology Clinical Trials Share (%), 2011 16
Figure 2: Novel Therapies in Oncology, Protein Kinase Inhibitors Molecules by Indication, 2011 27
Figure 3: Novel Therapies in Oncology, Vaccine Molecules by Indication, 2011 28
Figure 4: Novel Therapies in Oncology, Metastatic Breast Cancer Opportunity and Unmet Need Analysis, 2011 31
Figure 5: Novel Therapies in Oncology, Adjuvant Breast Cancer Opportunity and Unmet Need Analysis, 2011 32
Figure 6: Novel Therapies in Oncology, Colorectal Cancer Opportunity and Unmet Need Analysis, 2011 33
Figure 7: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, First-line Therapy, 2011 34
Figure 8: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, Second line Therapy, 2011 35
Figure 9: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, First line Therapy, 2011 36
Figure 10: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, Second Line Therapy, 2011 37
Figure 11: Novel Therapies in Oncology, Prostate Cancer Opportunity and Unmet Need Analysis, 2011 38
Figure 12: Novel Therapies in Oncology, Ovarian Cancer Opportunity and Unmet Need Analysis, 2011 39
Figure 13: Novel Therapies in Oncology, Cervical Cancer Opportunity and Unmet Need Analysis, 2011 40
Figure 14: Novel Therapies in Oncology, Head and Neck Cancer Opportunity and Unmet Need Analysis, 2011 41
Figure 15: Novel Therapies in Oncology, Pipeline by Developmental Phase (%), 2011 43
Figure 16: Novel Therapies in Oncology, Pipeline by Indication (%), 2011 44
Figure 17: Novel Therapies in Oncology, Pipeline by Therapeutic Class (%), 2011 45
Figure 18: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase (%), 2011 47
Figure 19: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 48
Figure 20: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 49
Figure 21: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 50
Figure 22: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 51
Figure 23: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 52
Figure 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase (%), 2011 62
Figure 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 63
Figure 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 64
Figure 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 65
Figure 28: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 66
Figure 29: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 67
Figure 30: Novel Therapies in Oncology, NHL Pipeline by Phase (%), 2011 75
Figure 31: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 76
Figure 32: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 77
Figure 33: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 78
Figure 34: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 79
Figure 35: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 80
Figure 36: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase (%), 2011 86
Figure 37: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 87
Figure 38: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 88
Figure 39: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 89
Figure 40: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 90
Figure 41: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 91
Figure 42: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011 92
Figure 43: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase (%), 2011 99
Figure 44: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 100
Figure 45: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 102
Figure 46: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 103
Figure 47: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 104
Figure 48: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011 105
Figure 49: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase (%), 2011 112
Figure 50: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 113
Figure 51: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 114
Figure 52: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 115
Figure 53: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 116
Figure 54: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase (%), 2011 123
Figure 55: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 124
Figure 56: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 125
Figure 57: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 126
Figure 58: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 127
Figure 59: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase (%), 2011 130
Figure 60: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 131
Figure 61: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 132
Figure 62: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 133
Figure 63: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 134
Figure 64: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018 140
Figure 65: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018 142
Figure 66: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018 144
Figure 67: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018 145
Figure 68: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018 146
Figure 69: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2014-2018 148
Figure 70: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018 149
Figure 71: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018 151
Figure 72: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018 153
Figure 73: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011 156
Figure 74: Novel Therapies in Oncology, Global, M&A Deals by Geography, (%), 2007-2011 157
Figure 75: Novel Therapies in Oncology, Global, M&A Deals by Value, (%), 2007-2011 158
Figure 76: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, (%), 2007-2011 159
Figure 77: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011 161
Figure 78: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, (%), 2007-2011 162
Figure 79: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, (%), 2007-2011 163
Figure 80: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 165
Figure 81: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, (%), 2007-2011 166
Figure 82: Novel Therapies in Oncology, Global, Co-Development Deals by Value, (%), 2007-2011 167

Upcoming Reports:

Blood-Brain Barrier Technologies Market - Global Industry Analysis, Market Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Blood brain barriers are endothelial cells covering the capillaries of the brain. Some of the functions of these blood-brain barriers are: Preventing pathogens (bacteria and viruses) and immune cells from entering the brain Excluding and metabolizing neurotoxic compounds (drugs, antibodies and plasma proteins) and neurotransmitters from brain and blood Safeguarding neurons’ ion balances Rising global prevalence of Parkinson’s disease, cardiovascular diseases and rapidly aging world’s population are some of the drivers for the blood-brain...
Merchant-Paid Rewards Market: Industry Analysis, Market Size, Share, Trends, Growth And Forecast, 2011 - 2018
By - Transparency Market Research
Debit card users are increasing in number as compared to credit card users. Use of debit card allows the consumers to save money for future use as they know how much money they have and how much money they have to spend. This trend leads to the growth of merchant paid reward programs. Credit cards do not give customers this privilege as they pay later for whatever they have purchased. Merchant-paid programs persuade customers to use their debit cards rather than credit cards or paper coupons. Merchant paid programs are gaining popularity in the market as it offers...
Drug Discovery Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Drug discovery is a process of inventing a new medication in the field of pharmaceuticals, biotechnology and pharmacology. Drug discovery is a complex, lengthycomplicated and expensive process. This process is carried out in four stages namely, target identification, target validation, high-speed screening and lead optimization. Though advanced technologies are available, success rate of drug discovery is very low and the time involved is relatively high.  The final stage of drug discovery involves obtaining a patent and running clinical trials. Most of the drugs entering into...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014  
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...